EXHIBIT
4.1


 


DESCRIPTION
OF THE REGISTRANT’S SECURITIES


REGISTERED
PURSUANT TO SECTION 12 OF THE


SECURITIES
EXCHANGE ACT OF 1934


 


As
of December 31, 2020, Aditx Therapeutics, Inc. (“the Company”) had one class of security registered under Section 12
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our common stock, par value $0.001 per share
(“Common Stock”).


 


Description
of Common Stock


 


The
following description of our Common Stock is a summary and does not purport to be complete. It is subject to and qualified
in its entirety by reference to our Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”)
and our Amended and Restated Bylaws (the “Bylaws”), each of which are incorporated by reference as an exhibit to the
Annual Report on Form 10-K of which this Exhibit 4.1 is a part. We encourage you to read our Certificate of Incorporation,
Bylaws, and the applicable provisions of the Delaware General Corporation Law for additional information.


 


Authorized
Capital Shares


 


Our
authorized capital shares consist of 27,000,000 shares of common stock, $0.001 par value per share, and 3,000,000 shares of preferred
stock, $0.001 par value per share (“Preferred Stock”). As of December 31, 2020, there were 13,074,495 shares
of common stock issued and 12,973,692 shares of common stock outstanding. There were no shares of Preferred Stock
issued or outstanding as of December 31, 2020.


 


Voting
Rights


 


Holders
of common stock are entitled to one vote per share on all matters voted on by the stockholders, including the election of directors.
Our Certificate of Incorporation and Bylaws do not provide for cumulative voting in the election of directors.


 


Dividend
Rights


 


Holders
of the Company’s common stock are entitled to receive dividends, if any, as may be declared from time to time by the board
of directors in its discretion out of funds legally available for the payment of dividends.


 


Liquidation
Rights


 


In
the event of our liquidation, the holders of our common stock will be entitled to share ratably in any distribution of our assets
after payment of all debts and other liabilities and the preferences payable to holders of shares of Preferred Stock then outstanding,
if any.


 


Applicable
Anti-Takeover Law


 


Set
forth below is a summary of the provisions of the Certificate of Incorporation and the Bylaws that could have the effect of delaying
or preventing a change in control of the Company. The following description is only a summary and it is qualified by refence to
the Certificate of Incorporation, the Bylaws and relevant provisions of the Delaware General Corporation Law.


 






     


     


    

 


Blank
Check Preferred Stock


 


The
Certificate of Incorporation authorizes 3,000,000 undesignated shares of Preferred Stock and permits our board of directors to
issue Preferred Stock with rights or preferences that could impede the success of any attempt to change control of the Company.
For example, our board of directors, without stockholder approval, may create or issue Preferred Stock with conversion rights
that could adversely affect the voting power of the holders of our common stock as well as rights to such Preferred Stock, in
connection with implementing a stockholder rights plan. This provision may be deemed to have a potential anti-takeover effect,
because the issuance of such Preferred Stock may delay or prevent a change of control of the Company. Furthermore, shares of Preferred
Stock, if any are issued, may have other rights, including economic rights, senior to common stock, and as a result, the issuance
thereof could depress the market price of our common stock.


 


No
Cumulative Voting


 


The
Certificate of Incorporation and the Bylaws do not provide holders of our common stock cumulative voting rights in the election
of directors. The absence of cumulative voting could have the effect of preventing stockholders holding a minority of our shares
of common stock from obtaining representation on our board of directors. The absence of cumulative voting might also, under certain
circumstances, render more difficult or discourage a merger, tender offer or proxy contest favored by a majority of our stockholders,
the assumption of control by a holder of a large block of our stock or the removal of incumbent management.


 


Advance
Notice Requirements for Stockholder Proposals and Director Nominees


 


The
Bylaws require stockholders seeking to make nominations of candidates for election as directors or to bring other business before
a meeting of our stockholders to provide timely notice of their intent in writing. To be timely, a stockholder’s notice
must be delivered to the Secretary at our principal executive offices not less than 90 days nor more than 120 days prior to the
first anniversary of the immediately preceding annual meeting of the stockholders; provided, however, that in the event that the
date of the annual meeting is more than 30 days before or after such anniversary date, notice by the stockholder to be timely
must be so received not later than the close of business on the tenth day following the earlier of the date on which we first
give notice or publicly announce the date of the meeting. A stockholder’s notice must include certain information about
the stockholder and the nominee or proposal as specified in the Bylaws. These advance notice provisions may restrict the ability
of the stockholders to make nominations for directors at or bring business before a meeting of the Company’s stockholders.


 


Listing


 


Our
common stock is traded on Nasdaq Capital Market under the trading symbol “ADTX”.


 


Transfer
Agent


 


The
Company’s transfer agent is VStock Transfer, LLC.